JCR Pharmaceuticals Co., Ltd. - Laporan Laba Rugi (TTM)

JCR Pharmaceuticals Co., Ltd.
DE ˙ DB ˙ JP3701000006
Laporan Laba Rugi (TTM)

Laporan Laba Rugi JCR Pharmaceuticals Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 24,496 26,128 30,085 34,717 47,517 50,931 51,082 50,875 38,280 37,508 34,343 35,545 43,034 41,365 42,871 40,208 35,256 35,033 33,072 33,496
Change (%) 6.66 15.14 15.40 36.87 7.18 0.30 -0.41 -24.76 -2.02 -8.44 3.50 21.07 -3.88 3.64 -6.21 -12.32 -0.63 -5.60 1.28
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 8,241 7,823 7,812 8,404 8,784 8,827 10,461 11,270 10,812 10,534 8,886 9,316 9,931 10,410 11,620 10,330 10,069 10,204 11,333 11,617
Change (%) -5.07 -0.14 7.58 4.52 0.49 18.51 7.73 -4.06 -2.57 -15.64 4.84 6.60 4.82 11.62 -11.10 -2.53 1.34 11.06 2.51
% of Revenue 33.64 29.94 25.97 24.21 18.49 17.33 20.48 22.15 28.24 28.08 25.87 26.21 23.08 25.17 27.10 25.69 28.56 29.13 34.27 34.68
Gross Operating Profit 16,255 18,305 22,273 26,313 38,733 42,104 40,621 39,605 27,468 26,974 25,457 26,229 33,103 30,955 31,251 29,878 25,187 24,829 21,739 21,879
Change (%) 12.61 21.68 18.14 47.20 8.70 -3.52 -2.50 -30.65 -1.80 -5.62 3.03 26.21 -6.49 0.96 -4.39 -15.70 -1.42 -12.45 0.64
% of Revenue 66.36 70.06 74.03 75.79 81.51 82.67 79.52 77.85 71.76 71.92 74.13 73.79 76.92 74.83 72.90 74.31 71.44 70.87 65.73 65.32
SG&A 6,685 7,243 8,624 10,483 12,771 14,071 13,511 13,943 13,252 13,267 11,678 11,921 13,172 14,321 23,719 24,708 14,058 25,860 12,958 28,839
Change (%) 8.35 19.07 21.56 21.83 10.18 -3.98 3.20 -4.96 0.11 -11.98 2.08 10.49 8.72 65.62 4.17 -43.10 83.95 -49.89 122.56
% of Revenue 27.29 27.72 28.67 30.20 26.88 27.63 26.45 27.41 34.62 35.37 34.00 33.54 30.61 34.62 55.33 61.45 39.87 73.82 39.18 86.10
R&D 5,997 5,997 5,360 5,360 5,360 5,360 7,175 7,175 7,175 7,175 8,802 8,802 8,802 8,802 11,234 15,431
Change (%) 0.00 -10.62 0.00 0.00 0.00 33.86 0.00 0.00 0.00 22.68 0.00 0.00 0.00
% of Revenue 24.48 22.95 17.82 15.44 11.28 10.52 14.05 14.10 18.74 19.13 25.63 24.76 20.45 21.28 31.86 46.66
OpEx 20,923 21,063 21,796 24,247 26,915 28,258 31,147 32,388 31,239 30,976 29,366 30,039 31,905 33,533 35,339 35,252 35,459 36,207 39,913 40,471
Change (%) 0.67 3.48 11.25 11.00 4.99 10.22 3.98 -3.55 -0.84 -5.20 2.29 6.21 5.10 5.39 -0.25 0.59 2.11 10.24 1.40
% of Revenue 85.41 80.61 72.45 69.84 56.64 55.48 60.97 63.66 81.61 82.59 85.51 84.51 74.14 81.07 82.43 87.67 100.58 103.35 120.69 120.82
Operating Income 3,573 5,065 8,289 10,470 20,602 22,673 19,935 18,487 7,041 6,532 4,977 5,506 11,129 7,832 7,532 4,956 -203 -1,174 -6,841 -6,975
Change (%) 41.76 63.65 26.31 96.77 10.05 -12.08 -7.26 -61.91 -7.23 -23.81 10.63 102.12 -29.63 -3.83 -34.20 -104.10 478.33 482.71 1.96
% of Revenue 14.59 19.39 27.55 30.16 43.36 44.52 39.03 36.34 18.39 17.41 14.49 15.49 25.86 18.93 17.57 12.33 -0.58 -3.35 -20.69 -20.82
Interest Expense -30 -36 -42 -44 -46 -45 -45 -45 -44 -45 -44 -53 -63 -74 -86 -93 -109 -126 -155 -208
Change (%) 20.00 16.67 4.76 4.55 -2.17 -0.00 -0.00 -2.22 2.27 -2.22 20.45 18.87 17.46 16.22 8.14 17.20 15.60 23.02 34.19
% of Revenue -0.12 -0.14 -0.14 -0.13 -0.10 -0.09 -0.09 -0.09 -0.11 -0.12 -0.13 -0.15 -0.15 -0.18 -0.20 -0.23 -0.31 -0.36 -0.47 -0.62
Net Income 2,983 4,137 6,892 7,657 14,899 16,549 14,507 14,343 6,235 5,154 3,772 4,014 8,063 5,364 5,507 4,098 -437 -229 -4,759 -5,506
Change (%) 38.69 66.59 11.10 94.58 11.07 -12.34 -1.13 -56.53 -17.34 -26.81 6.42 100.87 -33.47 2.67 -25.59 -110.66 -47.60 1,978.17 15.70
% of Revenue 12.18 15.83 22.91 22.06 31.36 32.49 28.40 28.19 16.29 13.74 10.98 11.29 18.74 12.97 12.85 10.19 -1.24 -0.65 -14.39 -16.44

Source: Capital IQ

Other Listings
JP:4552 JP¥ 646.00
US:JCRRF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista